Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02378701 · ClinicalTrials.gov registry record
Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 102
- Enrollment target
NCT02378701: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT02378701 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02378701 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 102 participants
- Enrollment target
Study Summary
The goal of this research study is to test a quality-of-life questionnaire called QUALMS-1 in patients with MDS. This is an investigational study. Up to 240 participants will be enrolled in this multicenter study. Up to 175 will take part at MD Anderson.
Interventions
- BEHAVIORAL QUALMS-1 Questionnaire
- BEHAVIORAL FACT-An Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2015-02 |
| Est. Completion | 2022-07-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02378701
The ClinicalTrials.gov registry entry for NCT02378701 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QUALMS-1 Questionnaire is the first listed.
NCT02378701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02378701 about?
NCT02378701 is a clinical study titled "Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease". The goal of this research study is to test a quality-of-life questionnaire called QUALMS-1 in patients with MDS. This is an investigational study. Up to 240 participants will be enrolled in this multicenter study. Up to 175 will take part at MD Anderson.
What is the current status of trial NCT02378701?
This trial is currently completed. The enrollment target is 102 participants. The study started on 2015-02. Estimated completion is 2022-07-18.
What interventions are being tested in trial NCT02378701?
The interventions under investigation include: QUALMS-1 Questionnaire (BEHAVIORAL), FACT-An Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT02378701?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.